Cite
APA Citation
Sermer, D., Vardhana, S., Batlevi, C., Hamilton, A., Moskowitz, A., Caron, P., Moskowitz, C., Matasar, M., Biggar, E., Leung, E., Yahalom, J., Rademaker, J., Dogan, A., Seshan, V., & Younes, A. (n.d.). sAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL). Hematological oncology, 37, 331–332. http://access.bl.uk/ark:/81055/vdc_100086191599.0x00004c